Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance

Gilead Sciences, Inc.Trade
State Street SPDR S&P Homebuilders ETFTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs State Street SPDR S&P Homebuilders ETF — how do they compare? Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B), while State Street SPDR S&P Homebuilders ETF trades at $108.31. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while State Street SPDR S&P Homebuilders ETF pays none. Which is the better fit depends on your goals.

GILDXHB
Market Cap
$168.35B
Sector
HealthBroad Market / Factor
52-Week High
$155.80$121.36
52-Week Low
$110.56$94.86
Enterprise Value
$191.42B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.

The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.

State Street SPDR S&P Homebuilders ETF

XHB trades at $108.35 with a slight 0.1% daily gain, showing bullish technical momentum with strong moving average support. The ETF benefits from positive housing market developments including new home sales growth and supportive legislation, though mixed economic data creates uncertainty. Technical indicators show overall bullish sentiment with 14 buy signals versus 3 sell signals.

The outlook remains cautiously optimistic as housing affordability legislation and seasonal demand provide tailwinds, but high mortgage rates and record home prices pose headwinds. Key risks include interest rate sensitivity and economic volatility, while institutional positioning suggests selective confidence in the homebuilding sector's recovery prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About State Street SPDR S&P Homebuilders ETF

XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.

Read more on XHB